Arranta Bio
Arranta Bio is a Watertown, MA-based CDMO specializing in microbiome, live biotherapeutic, xRNA, viral vector, and recombinant protein manufacturing, now operating as Recipharm Advanced Bio serving advanced-therapy biotech innovators.
- Company typePrivate
- Founded2019
- HeadquartersWatertown, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Arranta Bio does
Arranta Bio is a United States-based contract development and manufacturing organization (CDMO) founded in 2019 and headquartered in Watertown, with 101–250 employees. The company was purpose-built to serve the microbiome and Live Biotherapeutic Products (LBP) segment, providing end-to-end process development, GMP manufacturing, and aseptic fill-finish for early- to late-stage clinical programs targeting novel biotherapeutics.
Following acquisition by Sweden-based Recipharm AB, Arranta now operates as Recipharm Advanced Bio (branded ReciBioPharm), broadening its modality footprint to include xRNA therapies (plasmid DNA, mRNA, lipid nanoparticles, including continuous manufacturing), viral vectors (AAV, lentivirus, oncolytic viruses), microbial and live biotherapeutic products, recombinant proteins, and GMP sterile fill-finish. The company differentiates via an integrated two-continent operating model, GMP-certified suites tailored to ATMPs, and a proprietary process platform branded Recimagine™ that combines continuous production, Process Analytical Technology (PAT), and a digital process simulator.
The business model is project- and program-based CDMO services revenue, with clinical and commercial manufacturing contracts, process-development fees, and increasingly platform/licensing income tied to Recimagine™ assets and inbound collaborations (University of Oxford, NewBiologix, LenioBio, Hongene Biotech). Customer concentration specifics are not disclosed, but the client base appears to be advanced-therapy biotech innovators seeking regulatory-grade manufacturing for hard-to-produce modalities. Strategic ownership sits with Recipharm AB following the integration of Arranta as its advanced-therapies arm.
Arranta Bio firmographics
Firmographics- Name
- Arranta Bio
- Legal name
- Arranta Bio
- Website
- https://arrantabio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Arranta Bio is a Watertown, MA-based CDMO specializing in microbiome, live biotherapeutic, xRNA, viral vector, and recombinant protein manufacturing, now operating as Recipharm Advanced Bio serving advanced-therapy biotech innovators.
- Ownership category
- akta.pro rank
Arranta Bio industry classification
Industry- Product category
- Biopharmaceutical CDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD), Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Arranta Bio is headquartered
LocationHeadquarters
- HQ city
- Watertown
- HQ country
- United States
- HQ region
- North America
Markets served
Arranta Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
Arranta Bio product offering
Product offeringCore offering
Arranta Bio (now Recipharm Advanced Bio) is a contract development and manufacturing organization (CDMO) providing end-to-end process development and GMP manufacturing services for advanced therapeutic medicinal products (ATMPs). Its service portfolio spans xRNA therapies, plasmid DNA, lipid nanoparticles, viral vectors, microbial and live biotherapeutic products, recombinant proteins, and sterile fill-finish, serving biopharma sponsors across two continents.
Differentiator
Problem solved
Functional benefit
Products and services
- xRNA Therapies End-to-end contract development and GMP manufacturing services for xRNA-based therapeutics, including plasmid DNA production, xRNA synthesis, lipid nanoparticle (LNP) formulation, and continuous xRNA manufacturing. Targeted at biopharma developers of mRNA and next-generation RNA medicines.
- Plasmid DNA Manufacturing Contract development and GMP manufacturing of plasmid DNA used as a starting material for xRNA therapies and viral vector production. Serves gene therapy and xRNA therapeutic developers.
- Lipid Nanoparticle (LNP) Services Contract development and manufacturing of lipid nanoparticles for encapsulation and delivery of xRNA payloads. Targeted at sponsors developing RNA-based drugs and vaccines.
- Virus & Viral Vectors Contract development and GMP manufacturing of viral vectors including AAV and lentivirus assets, oncolytic and unique viruses, plus cell, bacteria and virus banking. Serves gene therapy developers.
- Cell, Bacteria & Virus Banking GMP-compliant cell, bacteria, and virus banking services to establish and store master and working banks used as starting materials for viral vector and advanced therapy manufacturing programs.
- Microbial & Live Biotherapeutic Products Contract process development and GMP manufacturing for microbial strains and live biotherapeutic products (LBPs). Targeted at microbiome therapeutic developers and biopharma sponsors advancing LBPs into clinical and commercial stages.
- Recombinant Proteins Contract development and GMP manufacturing of recombinant proteins using microbial expression systems. Serves biopharma developers of protein-based therapeutics.
- GMP Sterile Fill-Finish GMP-compliant sterile fill-finish services for advanced therapy drug products, providing final drug-product manufacturing capacity for clinical and commercial supply.
- Recimagine™ Continuous Production System Proprietary continuous production platform within the Recimagine™ ecosystem that integrates unit operations to support continuous manufacturing of advanced therapies. Targeted at sponsors seeking reduced timelines and process intensification versus traditional batch manufacturing.
Companies that use Arranta Bio
Customer profileIdeal customer profiles1 record
Arranta Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Arranta Bio partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights4 records
Arranta Bio competitors and assessment
Company assessmentBroad incumbents
- Lonza: One of the world's largest CDMOs offering biologics, cell and gene therapy, and microbial manufacturing. Comparable to Arranta across the biologics, viral vector, and microbial/LBP CDMO modalities it serves.
- Catalent: Major global CDMO with deep capabilities in biologics, viral vectors, and cell therapy, including fill-finish. Directly comparable to Arranta's end-to-end advanced therapy offering and large-scale GMP manufacturing footprint.
- Samsung Biologics: Large-scale biologics CDMO offering mammalian cell culture manufacturing and fill-finish. Comparable as a contract manufacturer of recombinant biologics, with similar client base in pharma and biotech.
- FUJIFILM Diosynth Biotechnologies: Global CDMO with strong biologics, viral vector, and microbial fermentation capabilities, including live biotherapeutic manufacturing. A direct competitor for Arranta's recombinant protein and microbial/LBP contracts.
- WuXi Biologics: Leading global biologics CDMO with end-to-end development and manufacturing services. Comparable in offering recombinant protein, viral vector, and integrated drug substance / drug product services similar to Arranta's stack.
- Thermo Fisher Scientific (Patheon / Brammer Bio): Operates a large pharma services / CDMO business including viral vector manufacturing (via Brammer Bio) and biologics. Competes with Arranta for advanced therapy and biologics manufacturing programs.
Direct peers
- AGC Biologics: CDMO offering mammalian and microbial biologics, cell and gene therapy, and fill-finish. Closely comparable to Arranta's multi-modality, mid-size advanced therapy CDMO profile and includes former Cobra Biologics viral vector operations.
- Vibalogics: Specialist CDMO focused on viral vectors, vaccines, and oncolytic viruses for advanced therapies. Directly comparable to Arranta's viral vector and oncolytic virus modalities within the advanced therapy CDMO space.
- Biovian: European CDMO providing microbial fermentation, viral vector, and fill-finish services. Comparable to Arranta's microbial/LBP and viral vector capabilities, especially for early- to mid-stage advanced therapy clients.
Emerging players
- Resilience: Newer CDMO platform building integrated biologics, viral vector, and nucleic acid manufacturing capacity. Comparable as a multi-modality advanced therapy CDMO competing for similar biotech clients as Arranta.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Arranta Bio social profiles
Digital presenceArranta Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arranta Bio leadership team
Management profileNumber of profiles
Profiles3 records
Arranta Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arranta Bio M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arranta Bio
What does Arranta Bio do?
Arranta Bio (now Recipharm Advanced Bio) is a contract development and manufacturing organization (CDMO) providing end-to-end process development and GMP manufacturing services for advanced therapeutic medicinal products (ATMPs). Its service portfolio spans xRNA therapies, plasmid DNA, lipid nanoparticles, viral vectors, microbial and live biotherapeutic products, recombinant proteins, and sterile fill-finish, serving biopharma sponsors across two continents.
Is Arranta Bio a public or private company?
Arranta Bio is a private company. It is classified as corporate owned and is currently operating.
When was Arranta Bio founded?
Arranta Bio was founded in 2019. It employs 101 to 250 people.
Where is Arranta Bio based?
Arranta Bio is headquartered in Watertown, United States, in the North America region.
Who are Arranta Bio's main competitors?
Broad incumbents on record are Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, WuXi Biologics and Thermo Fisher Scientific (Patheon / Brammer Bio). Direct peers are AGC Biologics, Vibalogics and Biovian. Resilience is listed as an emerging player.
Does Arranta Bio have an API?
No public API is recorded for Arranta Bio.
What industry is Arranta Bio in?
Arranta Bio's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAGAD, Cell Banking & Viral Seed Services (MCB/WCB/VSB). Its NAICS code is 325414 and its SIC code is 2836.